Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

588
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
588
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

718
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
718
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

1.4K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.

Infection and drug resistance·2026
Same author

Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.

Emerging infectious diseases·2026
Same author

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial.

The lancet. HIV·2025
Same author

Quantitation of Plasma Bedaquiline Concentrations in Indian MDR-TB Patients Using Liquid Chromatography-Tandem Mass Spectrometry.

Biomedical chromatography : BMC·2025
Same author

Contribution of Key Comorbidities to Unfavorable Treatment Outcomes Among Adults With Drug-Sensitive Pulmonary TB in India: A Prospective Cohort Analysis.

Chest·2025

Related Experiment Video

Updated: Mar 7, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

22.6K

Tuberculosis Associated with HIV Infection.

Jeffrey A Tornheim1, Kelly E Dooley2

  • 1Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD 21287.

Microbiology Spectrum
|February 25, 2017
PubMed
Summary

HIV and tuberculosis (TB) co-infection is a significant global health challenge. Early screening for latent TB infection (LTBI) and parallel treatment initiation for both conditions improve outcomes for coinfected individuals.

More Related Videos

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

12.7K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Related Experiment Videos

Last Updated: Mar 7, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

22.6K
Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

12.7K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Tuberculosis (TB) is now the leading infectious disease killer, surpassing HIV, with a lethal synergy between the two.
  • HIV disproportionately affects TB burden, especially where poverty is prevalent, creating a bidirectional impact on disease progression.
  • HIV increases TB risk, while TB accelerates AIDS progression and mortality in HIV-infected individuals.

Purpose of the Study:

  • To outline current recommendations for managing TB and HIV co-infection.
  • To emphasize the importance of screening, diagnosis, and treatment strategies for coinfected patients.
  • To highlight drug-drug interactions and treatment timing considerations.

Main Methods:

  • Review of current guidelines for managing co-infection.
  • Discussion of diagnostic methods including Tuberculin Skin Tests (TSTs), Interferon Gamma Release Assays (IGRAs), and nucleic acid amplification tests.
  • Analysis of treatment protocols, including antiretroviral therapy (ART), latent TB infection (LTBI) treatment, and drug susceptibility testing.

Main Results:

  • Antiretroviral therapy (ART) and latent TB infection (LTBI) treatment are crucial for mitigating co-infection impact.
  • LTBI screening is recommended for all HIV-positive individuals at diagnosis, with follow-up screenings.
  • Parallel treatment initiation for TB and HIV, especially for those with low CD4 counts, reduces mortality.

Conclusions:

  • Integrated management of TB and HIV co-infection is essential for improving patient outcomes.
  • Adherence to screening, timely diagnosis, and appropriate treatment strategies, including managing drug interactions, is critical.
  • Further research may be needed to optimize management in resource-limited settings.